ADHERENCE TO PROTEASE INHIBITORS

描述(摘自摘要)：蛋白酶抑制剂需要 艾滋病病毒(PWHIV)感染者要严格遵守 治疗方案。只是少了几剂或改变了间隔 两剂之间可能会导致病毒载量增加，CD4T细胞减少 以及耐药突变株的发展。研究人员 正面临着证明干预措施的有效性的挑战 提高依从性；然而，没有对谁是PWHIV的干预研究 服用包括蛋白酶抑制剂在内的联合治疗一直是 出版了。因此，这项研究的主要目的是比较 平时习惯训练和问题解决干预的效果观察 注意坚持联合治疗，包括一种蛋白水解酶抑制剂。 这项为期12个会议的电话干预和12周维护计划是 以社会学习理论和自我效能感理论为基础。样本 在接受包括蛋白酶在内的联合治疗的200名PWHIV患者中 抑制剂，并且没有认知功能障碍、酒精和/或 注射吸毒和/或慢性情绪障碍/个性 障碍将被随机分配到两个礼仪武器中的一个。这个 干预组将接受电话传递的为期12周的干预 然后是为期3个月的每周电话维护计划。数据 将在基线、治疗后、维护后和6- 维修后数月。药品电子监控系统(MEMS) 将使用TrackCaps、每日日记和药片计数来评估 坚持不懈。疗效调节剂将使用医疗结果来衡量 研究-HIV(情绪和身体功能)，症状苦恼量表，以及 贝克抑郁量表-II。将使用以下方法评估临床反应 病毒载量和CD4T细胞计数。一种有计划的重复测量模型 比较将被用来检验主要目的的假设。 (P&lt；0.05，双尾)。将使用纵向数据分析技术。 坚持治疗的PWHIV患者将活得更长，需要的时间更少 住院，护理技能较差，家庭护理较少，因此 降低他们的医疗保健成本。

DESCRIPTION (adapted from the Abstract): Protease inhibitors require persons with HIV (PWHIV's) infection to adhere strictly to the rigorous therapeutic regimen. Missing just a few doses or changing the intervals between doses may lead to increase in viral load, decreases in CD4 T-cell counts, and the development of drug-resistant mutant strains. Researchers are being challenged to demonstrate the efficacy of interventions to enhance adherence; however, no intervention studies with PWHIV's who are taking combination therapy including protease inhibitors have been published. Therefore, the primary aim of this study is to compare the effect of the habit-training and problem-solving intervention with usual care on adherence to combination therapy including a protease inhibitor. This 12-session telephone intervention and 12-week maintenance program is based on social learning and theory and self-efficacy theory. The sample of 200 PWHIV's who are taking combination therapy including protease inhibitor, and who are without cognitive dysfunction, alcohol and/or injection drug abuse, and/or chronic emotional disorders/personality disorders will be randomly assigned to one of two protocol arms. The intervention arm will receive a telephone-delivered 12-week intervention followed by a 3-month maintenance program of weekly telephone calls. Data will be collected at baseline, post-treatment, post-maintenance, and 6- months post-maintenance. Medication Electronic Monitoring System (MEMS) TrackCaps, daily diaries, and pill counts will be used to assess adherence. Efficacy moderators will be measured using the Medical Outcomes Study-HIV (mood and physical function), the Symptom Distress Scale, and the Beck Depression Inventory-II. Clinical response will be assessed using viral load and CD4 T-cell count. A repeated-measures model with planned comparisons will be used to test the hypotheses for the primary aim (p<.05, two-tailed). Longitudinal data analytic techniques will be used. PWHIV's who adhere to therapy will live longer and require fewer hospitalizations, less skilled nursing care, and less home care, thus reducing the costs of their health care.